Introduction: In the REFLECT trial, lenvatinib was found to be noninferior compared to
sorafenib in terms of overall survival. Here, we analyze the effects of lenvatinib in the real-life …

Background Sorafenib is the only systemic agent to show statistically significant overall
survival (OS) benefits in advanced HCC. Erlotinib is a direct and reversible EGFR tyrosine …

Abstract On August 16, 2018, the US Food and Drug Administration approved lenvatinib
(Lenvima, Eisai Inc.) for first‐line treatment of patients with unresectable hepatocellular …

Introduction: With growing knowledge of the molecular pathway of carcinogenesis, targeted
therapies have become the 'blue ocean'of cancer treatment. sorafenib is an oral multikinase …

Background: Lenvatinib is approved for patients with advanced hepatocellular carcinoma
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …

Aims Currently, the only standard systemic treatment for advanced hepatocellular carcinoma
is sorafenib monotherapy. The study was conducted to assess the efficacy and safety of the …

Sorafenib is the first and only po administrated drug currently approved to treat advanced
hepatocellular carcinoma (HCC). However, concerns have been raised about sorafenib …

Background Sorafenib and lenvatinib are first‐line systemic therapies for unresectable
hepatocellular carcinoma (HCC). However, the criteria for their selection remain unclear …

Hepatocellular carcinoma (HCC) is frequently diagnosed in the setting of chronic liver
disease and cirrhosis. The median survival after diagnosis is dismal. The treatment options …

Aim Lenvatinib (LEN) has recently become available as a first‐line tyrosine‐kinase inhibitor
(TKI) for unresectable hepatocellular carcinoma (u‐HCC). In patients who showed …